NPUK is governed by its Articles and Memorandum and run by a Board of Trustees.
Our Annual Reports review our performance each year and the progress we’re making against our aims and objectives.
Our Report and Financial Statements provide a financial review each year.
29.11.19
We are joining 140+ organisations in a call to all political parties to put children and young people at the heart of this General Election...
Read more19.11.19
Kim Stratton, Chief Executive Officer at Orphazyme, commented, “We are delighted with FDA’s decision to grant Breakthrough Therapy Designation to arimoclomol for NPC. Arimoclomol has been shown to have a clinically meaningful effect on disease progression in NPC that is further supported by a biomarker effect indicating an effect on the biological underpinnings of the disease and a favorable safety and tolerability profile. We are committed to bringing this product to patients as soon as possible. Breakthrough Therapy Designation is designed to expedite the development and review of products for serious diseases with the direct involvement of senior staff and we look forward to working closely with the FDA to further advance arimoclomol. Our preparations for filing in the US are underway and we are on track to submit a New Drug Application in H1 2020.”
Read more
